Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% ...

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to access life-changing weight loss medications.

Previous studies have related tirzepatide use with improved eGFR and urine albumin-creatinine ratio (UACR) among patients with type 2 diabetes (T2D) and overweight or obesity. It remains unclear ...